The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status

Zhao, Hengqiang; Yang, Gong

doi:10.3389/fonc.2021.643956

Cited by 18 publications

(11 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Beside triple-negative primary tumor, which is known to be the most aggressive, PR-positive primary breast carcinoma, shows more aggressive features in comparison to ER-positive carcinoma. [31][32][33][34] Research shows that this, as well, is the case with SM, and the signi cance of this study is that it provides prognostic data useful for possible early surgical treatment and fracture prevention.…”

Section: Discussionmentioning

confidence: 63%

Influence of receptor status and proliferation index in skeletal metastases of breast carcinoma on pathological fracture occurrence

Rajkovic

Simić

Djuričić

et al. 2022

Preprint

View full text Add to dashboard Cite

Purpose. Bones affected with metastatic breast carcinoma are prone to pathological fracture, impairing quality of life and survival rate. This study examined estrogen, progesterone, and HER2 receptors status, and Ki-67 index in skeletal metastases of breast carcinoma and their potential influence on pathological fracture occurrence.Methods. The study included 152 samples of skeletal metastasis of breast carcinoma, each obtained from an individual patient. Allred’s score was used for immunohistochemical interpretation. Clinical and radiological data were gathered from each patient`s history of the disease.Results. Femur stood out as an independent risk factor – it had a nine times higher chance for pathological fracture than other bones. Estrogen receptors, HER2, and Ki-67 status had no statistical significance for pathological fracture occurrence. Progesterone receptors showed significance for fracture development. The probability of fracture in progesterone receptor positive metastases was 68,1%, risk increasing with the rise of positive cells percentage, regardless of the expression intensity.Conclusion. Receptor status is important for skeletal metastases of breast carcinoma and can be used in clinical decision-making for systemic therapy and surgical treatment in fracture prevention.

show abstract

Section: Discussionmentioning

confidence: 63%

Influence of receptor status and proliferation index in skeletal metastases of breast carcinoma on pathological fracture occurrence

Rajkovic

Simić

Djuričić

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The influence of receptor status on patient survival after pathological fracture and the outcome of surgical treatment are also well documented. Triple‐negative tumors (PR/ER/HER2) are the most aggressive, whilst PR‐positive primary breast cancer shows more aggressive features in comparison to ER‐positive lesions 27,28 . Since PR and ER regulate each other's expression, various combinations of these receptors and HER2 receptor differ in their prognosis, with single PR+ (ER−) and HER2− patients having poorer prognosis than PR+ and ER+, also than single ER+ (PR−) in same HER2− subtype 29 …”

Section: Discussionmentioning

confidence: 99%

“…Triple-negative tumors (PR/ER/HER2) are the most aggressive, whilst PR-positive primary breast cancer shows more aggressive features in comparison to ER-positive lesions. 27,28 Since PR and ER regulate each other's expression, various combinations of these receptors and HER2 receptor differ in their prognosis, with single PR+ (ERÀ) and HER2À patients having poorer prognosis than PR+ and ER+, also than single ER+ (PRÀ) in same HER2À subtype. 29 Although various national and international guidelines exist as to the management of early and metastatic breast cancer, to the best of our knowledge, none of these guidelines provides any guidance as to how the receptor status of the SMs of these patients may help in the selection process by the orthopedic surgeon of the patients who are at high risk of pathological fractures and therefore require bone fixation.…”

Section: Discussionmentioning

confidence: 99%

Higher rate of progesterone receptor positivity in skeletal metastases of breast cancer with a pathological fracture vs those without fracture

Rajkovic

Charalambous

et al. 2023

Intl Journal of Cancer

View full text Add to dashboard Cite

Identifying risk factors for fracture occurrence in breast cancer (BC) skeletal metastases (SM) may guide the management of such bone deposits. There is sparse evidence regarding receptor status in SM and their relationship to fracture occurrence. Our study aimed to determine the relationship between estrogen (ER), progesterone (PR) and HER2 receptor status and Ki-67 index and fracture occurrence in SM of BC. Exactly 152 samples of SM of BC obtained from individual patients were evaluated. The status of the aforementioned receptors and Ki67 index were determined in SMs samples.Their expression was compared between SM that did and did not develop a fracture.Ninety-one cases sustained a pathological fracture at the SM site, and 61 did not.Patients who sustained a pathological fracture had a higher rate of PR positivity at their SMs as compared to those with no fracture. There was no significant difference between the two groups concerning ER, HER2+ or Ki67 status. SMs secondary to BC with a fracture are more likely to be PR positive than those with no fracture. Determining the receptor status in SMs may identify high-risk groups for fracture occurrence, and determining the PR status may also guide surgical and hormonal therapy.

show abstract

“…us, determining the site and status of breast tumor ER is vital to e ectively and successfully treat patients and ultimately improve outcomes and survival rates [12]. e results of the National Cancer Database and the Surveillance, Epidemiology, and End Results (SEER) program indicate that while single ER + or PR + tumor subtypes indicate a worse prognosis than ER+/PR + tumors, ER−/PR + tumors exhibit a similar prognosis to that of the ER−/PR−subtype [14][15][16]. Furthermore, the ER and PR status may change during the development and treatment of breast cancer [17].…”

Section: Discussionmentioning

confidence: 99%

Role of Estrogen Receptor-Positive/Negative Ratios in Regulating Breast Cancer

Zhang

Jiang

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

The alpha estrogen receptor (ERα) contributes to breast cancer progression and recent guidelines define ER positivity as ≥1% stained cells, and a few tumor tissues show no ERα expression at all or are at 100%. Although ER and aromatase inhibitors are widely used to treat hormone receptor-positive (HR+) breast cancer, their effect on tumor activity at different ERα levels remains unclear. Therefore, we investigated the role of ERα+/ERα− ratios in determining the ERα level. We used ERα stably transfected and wild-type MDA-MB-231 cells (MDA-MB-231Trans−ER and MDA-MB-231WT, respectively) as represented ER+ and ER− cells, respectively, and MCF-7 cells were the positive control. MDA-MB-231Trans−ER and MDA-MB-231WT cells were mixed and cocultured at a ratio of 0%, 20%, 40%, 70%, and 100%. Migration and invasion functions at different cell ratios were evaluated in vitro using the Transwell and scratch test. In a xenograft mouse model, the polarization of the tumor-associated (M2) macrophage and the expression of breast cancer gene 1 (BRCA1), human epidermal growth factor receptor 2 (HER2), vascular endothelial growth factor (VEGF), and tumor necrosis factor (TNF)-α were measured. The results showed that the cell invasion and migration were significantly higher at 40% and 70% than they were at other ratios. Additionally, in vivo, the 70% ERα+/ERα-ratio was a critical indicator of cell activity and cytokine expression. The highest M2 level and expression of VEGR, TNF-α, BRCA1, and HER2 were shown at a ratio of 70%. Moreover, the effects of ERα were not linear in breast cancer, indicating that the ERα status requires continuous monitoring during long-term endocrine treatment. These results indicate that during HR+ breast cancer treatment, the ERα+/ERα− ratio may be a useful predictor and should be evaluated further.

show abstract

The Prognosis of Single Hormone Receptor-Positive Breast Cancer Stratified by HER2 Status

Cited by 18 publications

References 18 publications

Influence of receptor status and proliferation index in skeletal metastases of breast carcinoma on pathological fracture occurrence

Influence of receptor status and proliferation index in skeletal metastases of breast carcinoma on pathological fracture occurrence

Higher rate of progesterone receptor positivity in skeletal metastases of breast cancer with a pathological fracture vs those without fracture

Role of Estrogen Receptor-Positive/Negative Ratios in Regulating Breast Cancer

Contact Info

Product

Resources

About